Evidence map›Paper›PMID 31041717›Full record

Trial reportClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience.

A Parisi, E Palluzzi, A Cortellini, T Sidoni, V Cocciolone, P Lanfiuti Baldi, G Porzio, C Ficorella, K Cannita

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Paclitaxel-Induced Hepatotoxicity in Ovarian Cancer Patients: A Case Report.Journal of investigative medicine high impact case reports
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A ParisiMedical Oncology, St. Salvatore Hospital, Via Vetoio, 67100, L'Aquila, Italy. alexparis@hotmail.it.ORCID http://orcid.org/0000-0003-4629-7762
E PalluzziGynecologic Oncology Unit, Department of Women and Children Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
A CortelliniMedical Oncology, St. Salvatore Hospital, Via Vetoio, 67100, L'Aquila, Italy.
T SidoniDepartement of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
V CoccioloneDepartement of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
P Lanfiuti BaldiDepartement of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
G PorzioMedical Oncology, St. Salvatore Hospital, Via Vetoio, 67100, L'Aquila, Italy.
C FicorellaMedical Oncology, St. Salvatore Hospital, Via Vetoio, 67100, L'Aquila, Italy.
K CannitaDepartement of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the major challenges related to solvent-based taxanes administration in clinical practice is the high rate of hypersensitivity reactions (HSRs). Nab-paclitaxel is a solvent-free, albumin-bound, paclitaxel, which minimize the risk of HSR occurrence. In this single-institution, retrospective analysis, we evaluated stage IIIc-IV epithelial ovarian cancer (EOC) patients, treated with first-line carboplatin/nab-paclitaxel (± bevacizumab), after the occurrence of an HSR with solvent-based paclitaxel (and/or docetaxel). Between April 2012 and December 2018, ten patients (20.8%) received carboplatin/nab-paclitaxel (± bevacizumab) after the occurrence of an HSR to solvent-based taxanes. Among the evaluable patients, ORR was 100%. At median follow-up of 28.5 months, median PFS was 16.7 months, and median OS was 65.4 months, respectively. Median received dose intensity (DI) was 86% and 80% of the projected DI for nab-paclitaxel and carboplatin, respectively. There were no treatment-related grade 4 adverse events. Most relevant treatment-related grade 3 adverse events were: asthenia (10%), hypertransaminasemia (10%), neutropenia (20%), thrombocytopenia (20%), and anemia (10%). No HSR recurrence was observed. The high rate of HSR occurrence could limit first-line treatment options in clinical practice. Carboplatin/nab-paclitaxel association could represent a valid treatment option in this setting.

Indexed as

AdultAgedAlbuminsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinFemaleFollow-Up StudiesHumansHypersensitivityMiddle AgedOvarian NeoplasmsPaclitaxelPrognosisRetrospective StudiesSolventsTaxoids130-nm albumin-bound paclitaxelAlbuminsCarboplatinPaclitaxelSolventsTaxoidsHypersensitivity reactionNab-paclitaxelOvarian cancerSolvent-based taxanes

Identifiers

PMID31041717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.